Sam Lee의 보수는 Cocrystal Pharma의 수익에 비해 어떻게 변했나요?
날짜	총 보수	급여	회사 수익
Sep 30 2025	n/a	n/a	-US$10m
Jun 30 2025	n/a	n/a	-US$13m
Mar 31 2025	n/a	n/a	-US$16m
Dec 31 2024	US$681k	US$410k	-US$18m
Sep 30 2024	n/a	n/a	-US$19m
Jun 30 2024	n/a	n/a	-US$18m
Mar 31 2024	n/a	n/a	-US$17m
Dec 31 2023	US$627k	US$395k	-US$18m
Sep 30 2023	n/a	n/a	-US$18m
Jun 30 2023	n/a	n/a	-US$20m
Mar 31 2023	n/a	n/a	-US$40m
Dec 31 2022	US$622k	US$371k	-US$39m
Sep 30 2022	n/a	n/a	-US$38m
Jun 30 2022	n/a	n/a	-US$36m
Mar 31 2022	n/a	n/a	-US$16m
Dec 31 2021	US$665k	US$333k	-US$14m
Sep 30 2021	n/a	n/a	-US$12m
Jun 30 2021	n/a	n/a	-US$11m
Mar 31 2021	n/a	n/a	-US$10m
Dec 31 2020	US$462k	US$293k	-US$10m
Sep 30 2020	n/a	n/a	-US$56m
Jun 30 2020	n/a	n/a	-US$55m
Mar 31 2020	n/a	n/a	-US$53m
Dec 31 2019	US$241k	US$241k	-US$48m

보상 대 시장: Sam의 총 보수(USD680.86K)는 US 시장에서 비슷한 규모 기업의 평균(USD578.38K) 수준입니다.

보상과 수익: Sam의 보상은 회사가 적자임에도 증가했습니다.

CEO

Sam Lee (65 yo)

18yrs

재임 기간

US$680,859

보수

Dr. Sam Lee, Ph D., Co-founded Cocrystal Pharma, Inc. in 2008 and serves as its President since January 2, 2014 and serves as its Interim Co-Chief Executive Officer since May 2023 and had been its Interim...

리더십 팀

이름	직위	재임 기간	보수	지분
Roger Kornberg	Co-Founder	5.8yrs	US$209.97k	0.29% $ 38.9k
Sam Lee	Co-Founder	18yrs	US$680.86k	0.26% $ 35.6k
James Martin	Co-CEO, CFO & Corporate Secretary	8.6yrs	US$680.86k	0.32% $ 43.2k

18.0yrs

평균 재임 기간

65yo

평균 나이

경험이 풍부한 관리: COCP의 경영진은 노련하고 경험이 풍부합니다(평균 재임 18 년).

이사회 구성원

이름	직위	재임 기간	보수	지분
Roger Kornberg	Co-Founder	5.8yrs	US$209.97k	0.29% $ 38.9k
Fred Hassan	Independent Director	2.8yrs	US$50.50k	10.03% $ 1.4m
Richard Pfenniger	Independent Director	4.7yrs	US$50.50k	0.23% $ 30.7k
Phillip Frost	Independent Director	12yrs	US$92.47k	13.09% $ 1.8m
Steven Rubin	Independent Vice Chairman	12yrs	US$115.64k	0.014% $ 1.9k
Michael Levitt	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Gary Schoolnik	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Bob Lehman	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Roland Strong	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Christophe Verlinde	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Anthony Japour	Independent Director	6.8yrs	US$80.72k	0% $ 0
Baek Kim	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음

6.3yrs

평균 재임 기간

78yo

평균 나이

경험이 풍부한 이사회: COCP의 이사회는 경험이 있음으로 간주됩니다(평균 재임 6.3 년).

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/01/02 19:29
종가	2026/01/02 00:00
수익	2025/09/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Cocrystal Pharma, Inc.는 4명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Raghuram Selvaraju	H.C. Wainwright & Co.
Robert LeBoyer	NOBLE Capital Markets, Inc.
David Bautz	Zacks Small-Cap Research

Cocrystal Pharma 경영진

경영진 기준 점검 3/4

핵심 정보

최근 경영진 업데이트

Independent Director recently bought US$63k worth of stock

Cocrystal Pharma, Inc., Annual General Meeting, Jun 25, 2025

Cocrystal Pharma, Inc., Annual General Meeting, May 18, 2022

Board Member recently sold US$1.7m worth of stock

Board Member notifies of intention to sell stock

Board Member notifies of intention to sell stock

Recent updates

Independent Director recently bought US$63k worth of stock

Cocrystal Pharma, Inc. Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus

New major risk - Shareholder dilution

Cocrystal Pharma, Inc. announced that it has received $1.032803 million in funding

Cocrystal Pharma, Inc. Receives NIH SBIR Award to Advance Its Influenza Inhibitor Program

New minor risk - Shareholder dilution

Cocrystal Pharma, Inc. has completed a Follow-on Equity Offering.

Cocrystal Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $7.25 million.

Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in A Podium Presentation At the International Calicivirus Conference

Cocrystal Pharma, Inc. Receives Fda Ind Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor Cdi-988, A Potential First Antiviral for Norovirus Prevention and Treatment

Cocrystal Pharma, Inc. Presents Phase 1 Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference

Cocrystal Pharma, Inc. to Present Data from Phase 1 Study of First-In-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference

Cocrystal Pharma's Novel Norovirus Antiviral to Be Presented at Department of Defense Medical Conference

Cocrystal Pharma, Inc.'S Investigational Drug Candidate Cc-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5n1 Avian Influenza Strain

Cocrystal Pharma, Inc., Annual General Meeting, Jun 25, 2025

Cocrystal Pharma, Inc.'S Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants

Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug Cdi-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections

Cocrystal Pharma, Inc. to Extend Phase 2a Influenza Challenge Study with Oral PB2 Inhibitor CC-42344

New major risk - Share price stability

New major risk - Financial position

Here's Why We're Watching Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Situation

Price target decreased by 11% to US$8.00

Cocrystal Pharma, Inc. Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor

Cocrystal Pharma Advances Cc-42344 in Influenza A Phase 2A Study, Expects Topline Results by Late 2024

Cocrystal Pharma, Inc. Announces Completion of Enrollment of 78 Subjects

Cocrystal Pharma, Inc. Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investment Candidates

Cocrystal Pharma, Inc. Announces First-Patient-In for Phase 2A Human Challenge Study Evaluating Oral Cc-42344 in Pandemic and Seasonal Influenza A

Cocrystal Pharma, Inc. Highlights Its Novel Inhaled and Oral Influenza A Antiviral Cc-42344 At the World Vaccine Congress West Coast

Cocrystal Pharma, Inc. Doses First Subjects in Clinical Study of CDI-988 for Pandemic Norovirus and Coronavirus

Cocrystal Pharma, Inc. Announces Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma's Oral Antiviral Candidate Cc-42344

Cocrystal selects its antiviral drug candidate to develop as a treatment for COVID-19

Cocrystal Pharma Announces a 1-for-12 Reverse Stock Split

Consensus forecasts updated

Consensus forecasts updated

Cocrystal Pharma GAAP EPS of -$0.25 misses by $0.21

Cocrystal Pharma (NASDAQ:COCP) Is In A Good Position To Deliver On Growth Plans

Cocrystal Pharma Engages CRO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344

Cocrystal engages Open Orphan to conduct mid-stage trial of oral influenza drug in UK

Cocrystal Pharma, Inc. Reports CC-42344 Pharmacokinetic Data in Influenza A Once-Daily Dosing

Nasdaq Grants 180 Days to Cocrystal Pharma to Regain Compliance

Price target decreased to US$4.08

Cocrystal Pharma, Inc. Reports Favorable Preliminary Data from Phase 1 Initial Cohorts with Cc-42344, a Novel, Broad-Spectrum Influenza A Antiviral

Cocrystal Pharma, Inc., Annual General Meeting, May 18, 2022

We're Not Very Worried About Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate

Price target decreased to US$4.08

Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates for its COVID-19 Oral Drug Program

Cocrystal Pharma Receives FDA Guidance to Advance Clinical Development of its COVID-19 Antiviral CDI-45205

Cocrystal Pharma’s Covid-19 Oral and Intranasal/Pulmonary Protease Inhibitors Exhibit Powerful in Vitro Potency Against the Sars-Cov-2 Omicron Variant

Cocrystal Pharma to Discuss Progress with COVID-19 Antiviral Programs and Clinical Strategy During Noble Capital Markets’ Channelchek Virtual Roadshow

Companies Like Cocrystal Pharma (NASDAQ:COCP) Are In A Position To Invest In Growth

Third quarter 2021 earnings released: US$0.04 loss per share (vs US$0.046 loss in 3Q 2020)

We Think Cocrystal Pharma (NASDAQ:COCP) Can Afford To Drive Business Growth

Cocrystal Pharma, Inc. Completes IND-enabling Studies with CC-42344 for the Treatment of Seasonal and Pandemic Influenza A, Plans to initiate a Phase 1 Trial in the Third Quarter

CocrystalPharma, Inc ’s Lead COVID-19 Antiviral CDI-45205 Shown to be Active Against SARS-CoV-2 and Two Prominent SARS-CoV-2 Variants

Co-Founder, Chairman & CEO Gary Wilcox has left the company

Board Member recently sold US$1.7m worth of stock

We Think Cocrystal Pharma (NASDAQ:COCP) Needs To Drive Business Growth Carefully

Cocrystal Pharma, Inc. Provides Update on its COVID-19 Antiviral Discovery and Development Programs

Price target decreased to US$4.50

Full year 2020 earnings released: US$0.17 loss per share (vs US$1.51 loss in FY 2019)

Investors Who Bought Cocrystal Pharma (NASDAQ:COCP) Shares A Year Ago Are Now Up 94%

Board Member notifies of intention to sell stock

What Is The Ownership Structure Like For Cocrystal Pharma, Inc. (NASDAQ:COCP)?

Board Member notifies of intention to sell stock

Cocrystal Pharma Provides Summary of Upcoming Presentation at the Reimagine Health Research Symposium

Cocrystal Pharma Announces Further Development of Influenza A/B Antiviral Compounds by Merck Under Exclusive Worldwide License and Collaboration Agreement

New 90-day high: US$2.19

Is Cocrystal Pharma (NASDAQ:COCP) In A Good Position To Invest In Growth?

New 90-day high: US$1.71